

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 14.02.2025

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of financial results for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of the Board meeting held on 14<sup>th</sup> November 2024, and the subsequent submissions made on 16<sup>th</sup> November 2024, along with the financial results submitted on 19<sup>th</sup> November 2024 (including XBRL results submitted on 20<sup>th</sup> November 2024) and it was communicated in our earlier submission on 29<sup>th</sup> November, 2024, 18<sup>th</sup> December, 2024, 15<sup>th</sup> January, 2025 & 31<sup>st</sup> January 2025, that the limited review report (Standalone & Consolidated) would be submitted once the Peer Review Certificate of Statutory Auditor is renewed. In this regard, we would like to inform you that the Peer Review Certificate of Statutory Auditor has been renewed.

Further, with reference to the clarification mail on the financial results for period ended September, 2024 received on 22<sup>nd</sup> November, 2024, we wish to provide the following clarifications:

- 1. Machine Readable Form / Legible Copy of Financial Results Not Submitted:** The legible copy of the financial results is enclosed as *Annexure-I* to this letter.
- 2. Financial Results Not Submitted within 30 Minutes of the Board Meeting:** Kindly note that the reason for the delay in submitting the Financial Results was already communicated to the NSE on 16<sup>th</sup> November 2024, along with the outcome of the board meeting held on 14<sup>th</sup> November 2024. A copy of the clarification submitted is enclosed as *Annexure-II* to this letter for your reference.
- 3. Standalone & Consolidated Limited Review Reports Not Submitted:** The reason for the delay in submitting the signed Limited Review Reports (Standalone & Consolidated) was communicated to the NSE through the NEAPS portal on 29<sup>th</sup> November 2024, 18<sup>th</sup> December, 2024, 15<sup>th</sup> January, 2025 & 31<sup>st</sup> January 2025, a copy of said clarification is enclosed as *Annexure-III* to this letter for your reference. Further, we have enclosed the Limited Review Report (Standalone & Consolidated) as *Annexure-I* along with the unaudited financial statements (Standalone & Consolidated) to this letter.

We kindly request you to consider our financial results and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

## **DocMode Health Technologies Limited**

**(Previously known as Docmode Health Technologies Private Limited)**

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



**www.docmode.org**

Transforming Learning and Practice

---

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**



---

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
 CIN : U74999MH2017PLC297413  
 Balance Sheet as at September 30,2024

Indian Rupees in Lacs

Particulars		Note	September 30,2024	March 31,2024
<b>I. EQUITY AND LIABILITIES</b>				
<b>1 Shareholder's funds</b>				
(a)	Share capital	<b>3</b>	314.28	314.28
(b)	Reserves and surplus	<b>4</b>	672.53	724.19
(c)	Money received against share warrants		-	-
<b>2 Share application money pending allotment</b>				
<b>3 Non-current liabilities</b>				
(a)	Long Term Borrowings	<b>5</b>	252.24	438.20
(b)	Deferred Tax Liabilities (Net)		-	-
(c)	Other Long Term Liabilities		-	-
(d)	Long Term Provisions	<b>6</b>	62.37	66.28
<b>4 Current liabilities</b>				
(a)	Short Term Borrowings	<b>7</b>	693.03	479.82
(b)	Trade Payables	<b>8</b>	220.33	281.59
(c)	Other Current Liabilities	<b>9</b>	-	-
(d)	Short Term Provisions	<b>10</b>	398.50	357.35
<b>TOTAL</b>			<b>2,613.28</b>	<b>2,661.71</b>
<b>II. ASSETS</b>				
<b>1 Non-current assets</b>				
(a)	Property, Plant and Equipment and Intangible Assets	<b>11</b>		
	(i) Property, Plant and Equipment		136.14	95.21
	(ii) Intangible Assets		1.22	1.61
	(iii) Capital Work-In-Progress		-	-
	(iv) Intangible Assets under Development		979.77	849.92
(b)	Non Current Investments	<b>12</b>	110.10	110.10
(c)	Deferred Tax Assets (net)	<b>13</b>	18.09	18.71
(d)	Long-term Loans and Advances	<b>14</b>	18.58	7.58
(e)	Other Non Current Assets	<b>15</b>	12.91	13.13
<b>2 Current assets</b>				
(a)	Current Investments	<b>16</b>	26.41	16.24
(b)	Inventories	<b>17</b>	349.20	251.39
(c)	Trade Receivables	<b>18</b>	471.08	790.90
(d)	Cash and Cash Equivalents	<b>19</b>	209.99	308.76
(e)	Short Term Loans and Advances	<b>20</b>	264.40	198.17
(f)	Other Current Assets	<b>21</b>	15.40	-
<b>TOTAL</b>			<b>2,613.28</b>	<b>2,661.71</b>
Significant Accounting Policies		<b>2</b>		
The notes are integral parts of the financial statements				

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathedath**  
 Whole Time Director  
 DIN 02301881

Place : Mumbai  
 Date : November 14, 2024

  
**Hans Albert Lewis**  
 Wholetime Director & CFO  
 DIN: 02301853  
 PAN: ACOPL6883G  
 Place : Mumbai  
 Date : November 14, 2024

**DocMode Health Technologies Limited**  
(Formerly known as Docmode Health Technologies Private Limited)  
CIN : U74999MH2017PLC297413

**Standalone Statement of Financial Results for the Half year ended September 30, 2024**

Indian Rupees in Lacs

Particulars	For half year ended			For year ended	
	September 30,2024	March 31,2024	September 30,2023	March 31,2024	March 31,2023
	Unaudited	Unaudited	Audited	Audited	Audited
I. Revenue from Operations	2,041.81	1,640.31	2,360.42	4,000.73	3,287.84
II. Other Income	84.10	7.31	6.28	13.59	9.57
III. <b>Total Income (I + II)</b>	<b>2,125.91</b>	<b>1,647.62</b>	<b>2,366.70</b>	<b>4,014.33</b>	<b>3,297.41</b>
IV. <b>Expenses:</b>					
Cost of Materials Consumed	-	-	-	-	-
Cost of Services	135.88	80.89	206.07	286.96	94.47
Changes in inventories	(97.82)	1.19	0.39	1.58	(2.55)
Employee benefits Expense	178.80	202.84	292.37	495.21	555.62
Finance Costs	108.79	81.44	83.78	165.22	112.88
Depreciation and Amortization Expense	14.14	0.91	1.53	2.44	2.13
Other Expenses	1,837.16	1,438.18	1,590.16	3,028.34	2,265.72
Total expenses	2,176.96	1,805.44	2,174.31	3,979.75	3,028.27
V. <b>Profit before exceptional and extraordinary items and tax (III- IV)</b>	(51.05)	(157.82)	192.39	34.58	269.15
VI. Exceptional Items	-	-	-	-	-
VII. <b>Profit before extraordinary items and tax (V - VI)</b>	(51.05)	(157.82)	192.39	34.58	269.15
VIII. Extraordinary items	-	-	-	-	-
IX. <b>Profit before tax (VII- VIII)</b>	(51.05)	(157.82)	192.39	34.58	269.15
X. <b>Tax expense:</b>					
(1) Current tax	-	(38.00)	58.00	20.00	82.50
Less : MAT Credit Entitlement	-	-	-	-	-
(2) Deferred tax Liability/(Asset)	0.62	(3.43)	(0.85)	(4.28)	(7.49)
(3) Tax in respect of earlier years	-	0.26	(0.77)	(0.51)	(0.73)
(4) Profit / (Loss) of Prior Period Depreciation	0.62	(41.17)	56.38	15.21	74.28
XI. <b>Profit (Loss) for the period from continuing operations (IX-X)</b>	(51.66)	(116.64)	136.01	19.37	194.87
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-	-
XIV. <b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>	-	-	-	-	-
XV. <b>Profit (Loss) for the period (XI + XIV)</b>	<b>(51.66)</b>	<b>(116.64)</b>	<b>136.01</b>	<b>19.37</b>	<b>194.87</b>
XVI. <b>Earnings per equity share of Rs. 10 each</b>					
Basic	(1.64)	(3.71)	5.93	0.62	8.50
Diluted	(1.64)	(3.71)	5.93	0.62	8.50
Significant Accounting Policies					
The notes are integral parts of the financial statements					

1 The Above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing Regulations") have been approved by the Board of Directors at their respective meeting held on November 14, 2024. The Statutory Auditors of the company have carried out the audit of the aforesaid results for the half year and year ended 30th September, 2024. The Financial Results have been prepared in accordance with the Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with rule 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof.

2 As per Ministry of Corporate Affairs Notification dated February 16,2015, Companies Whose Securities are listed on SME Exchange as referred in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.

3 The above Standalone Financial Results have been reviewed by the Audit Committee and Approved by the Board of Directors at their respective meeting held on November 14, 2024 and have been audited by the Statutory Auditors of the Company

4 The Primary reporting of the company has been performed on the basis of business segment. The management of the company has evaluated the company's overall performance as one segment which is "Transforming Learning and Practice" and operates in a single business segment based on the nature of business, the risk and returns, the organisation structure and the internal control Financial systems. Accordingly, the figures appearing in these financial statements relate to the company's single business segment. The company has significant operations based in India, hence there are no reportable geographical segments in Standalone Financial Statements.

5 The Figures for half year ended on 31st March 2024 are the balancing figures between the audited figures in respect of the financial year and the reviewed year to date figures for the half year ended on 30th September 2024.

6 Previous period figures have been regrouped/reclassified and restated wherever considered necessary to make them comparable.

7 The balance appearing under the trade payables, Loans & Advances, Other Current Liabilities are subject to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.

8 The company has issued and allotted 8,49,600 equity shares of Rs. 10 Each at premium of Rs.69 Per Equity Share through Initial Public Offer Aggregating to Rs. 671.18 Lakhs. The details of utilization of the net IPO proceeds is mentioned below:

Particulars	As per Prospectus	Funds Utilised
Purchase of IT infrastructure and operating system	303.08	258.08
Meeting incremental working capital requirements	200.00	200.00
General corporate purposes	103.10	103.10

for DocMode Health Technologies Limited



**Paulson Paul Thazhathadath**  
Whole Time Director  
DIN 02301881

Place : Mumbai  
November 14, 2024



**Hans Albert Lewis**  
Whole Time Director & CFO  
DIN: 02301853  
PAN: ACOPL6883G

Place : Mumbai  
November 14, 2024

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
**Statement of Cash Flows for the period ended September 30, 2024**

Indian Rupees in Lacs

(A) CASH FLOW FROM OPERATING ACTIVITIES	September 30,2024	March 31,2024
Net Profit before Tax and Extraordinary Items	(51.05)	34.58
<b>Adjusted for</b>		
Depreciation	14.14	2.44
Profit on Sale of Fixed Assets	-	-
Provision for Gratuity	(3.91)	17.43
Interest Expenses	108.79	165.22
<b>Operating Profit before Working Capital changes</b>	67.98	219.66
Adjutments for changes in working capital		
(Increase)/Decrease in Inventories	(97.82)	1.58
(Increase)/Decrease in Trade and Other Receivables	319.82	38.56
(Increase)/Decrease in Short Loans & Advances	(66.23)	13.44
(Increase)/Decrease in Long term Loans & Advances	(11.00)	(7.46)
(Increase)/Decrease in Other Current Assets	(15.40)	-
Increase/(Decrease) in Trade Payables	(61.26)	(19.36)
Increase/(Decrease) in Other Non Current liabilities	-	-
Increase/(Decrease) in Current liabilities	-	(0.41)
Increase/(Decrease) in Short Term Provisions	41.15	202.32
<b>Cash generated from operations</b>	177.25	448.34
Direct Taxes Paid	-	0.51
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	177.25	448.85
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Sale/ (Purchase) of Fixed Assets	(184.53)	(741.73)
Sale/ (Purchase) of Investments	(10.17)	(6.41)
Rent Deposit paid to landlord for office premises	0.22	(6.67)
<b>NET CASH USED IN INVESING ACTIVITIES</b>	(194.48)	(754.81)
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds/(Repayment) from long term borrowings	(185.96)	(3.29)
Proceeds from Short Term Borrowings	213.20	73.37
Proceeds from issue of Shares	-	671.18
Interest paid	(108.79)	(165.22)
<b>NET CASH FROM FINANCING ACTIVITIES</b>	(81.55)	576.04
NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(98.78)	270.09
OPENING BALANCE OF CASH AND CASH EQUIVALANTS	308.76	38.68
CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	209.99	308.76

for DocMode Health Technologies Limited



**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881




**Hans Albert Lewis**  
Wholetime Director & CFO  
DIN: 02301853  
PAN: ACOPL6883G

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
Consolidated Balance Sheet as at September 30,2024


Indian Rupees in Lacs

Particulars	Note	September 30,2024	March 31,2024
<b>I. EQUITY AND LIABILITIES</b>			
<b>1 Shareholder's funds</b>			
(a) Share capital	<b>3</b>	314.28	314.28
(b) Reserves and surplus	<b>4</b>	671.09	723.20
(c) Money received against share warrants		-	-
Minority Interest	<b>5</b>	(0.02)	-
<b>2 Share application money pending allotment</b>			
		-	-
<b>3 Non-current liabilities</b>			
(a) Long Term Borrowings	<b>6</b>	252.24	438.20
(b) Deferred Tax Liabilities (Net)		-	-
(c) Other Long Term Liabilities		-	-
(d) Long Term Provisions	<b>7</b>	62.37	66.28
<b>4 Current liabilities</b>			
(a) Short Term Borrowings	<b>8</b>	693.03	479.82
(b) Trade Payables	<b>9</b>	218.88	279.30
(c) Other Current Liabilities	<b>10</b>	-	-
(d) Short Term Provisions	<b>11</b>	398.50	338.48
<b>TOTAL</b>		<b>2,610.37</b>	<b>2,639.56</b>
<b>II. ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Property, Plant and Equipment and Intangible Assets	<b>12</b>		
(i) Property, Plant and Equipment		136.14	95.21
(ii) Intangible Assets		1.22	1.61
(iii) Capital Work-In-Progress		-	-
(iv) Intangible Assets under Development		979.77	849.92
(b) Non Current Investments	<b>13</b>	110.00	110.00
(c) Deferred Tax Assets (net)	<b>14</b>	18.10	18.71
(d) Long-term Loans and Advances	<b>15</b>	2.68	0.03
(e) Other Non Current Assets	<b>16</b>	12.91	13.13
<b>2 Current assets</b>			
(a) Current Investments	<b>17</b>	26.41	16.24
(b) Inventories	<b>18</b>	360.36	251.39
(c) Trade Receivables	<b>19</b>	471.08	790.90
(d) Cash and Cash Equivalents	<b>20</b>	211.72	310.28
(e) Short Term Loans and Advances	<b>21</b>	264.59	182.15
(f) Other Current Assets	<b>22</b>	15.40	-
<b>TOTAL</b>		<b>2,610.37</b>	<b>2,639.56</b>
Significant Accounting Policies	<b>2</b>		
The notes are integral parts of the financial statements			

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881

Place : Mumbai  
Date : November 14, 2024

  
**Hans Albert Lewis**  
Whole Time Director & CFO  
DIN 02301853  
PAN: ACOPL6883G  
Place : Mumbai  
Date : November 14, 2024

**DocMode Health Technologies Limited**  
(Formerly known as Docmode Health Technologies Private Limited)  
CIN : U74999MH2017PLC297413  
Consolidated Statement of Financial Results for the Half year ended September 30, 2024

Indian Rupees in Lacs


Particulars	For half year ended			For year ended	
	September 30,2024	March 31,2024	September 30,2023	March 31,2024	March 31,2023
	Unaudited	Unaudited	Audited	Audited	Audited
I. Revenue from Operations	2,041.81	1,640.31	2,360.42	4,000.73	3,287.84
II. Other Income	84.10	7.31	6.28	13.59	9.57
<b>III. Total Income (I + II)</b>	<b>2,125.91</b>	<b>1,647.62</b>	<b>2,366.70</b>	<b>4,014.33</b>	<b>3,297.42</b>
<b>IV. Expenses:</b>					
Cost of Materials Consumed				-	-
Cost of Services	135.88	81.65	206.07	287.73	94.47
Changes in inventories	(108.97)	1.19	0.39	1.58	(2.55)
Employee benefits Expense	178.80	202.74	292.37	495.11	555.62
Finance Costs	109.26	81.94	83.78	165.72	112.89
Depreciation and Amortization Expense	14.14	0.91	1.53	2.44	2.13
Other Expenses	1,848.31	1,437.62	1,590.16	3,027.78	2,265.77
Total expenses	2,177.43	1,806.05	2,174.31	3,980.36	3,028.33
<b>V. Profit before exceptional and extraordinary items and tax (III- IV)</b>	<b>(51.52)</b>	<b>(158.42)</b>	<b>192.39</b>	<b>33.97</b>	<b>269.09</b>
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	(51.52)	(158.42)	192.39	33.97	269.09
VIII. Extraordinary items					
IX. Profit before tax (VII- VIII)	(51.52)	(158.42)	192.39	33.97	269.09
<b>X. Tax expense:</b>					
(1) Current tax	-	(38.00)	58.00	20.00	82.50
Less : MAT Credit Entitlement					
	-	(38.00)	58.00	20.00	82.50
(2) Deferred tax Liability/(Asset)	0.62	(3.43)	(0.85)	(4.28)	(7.50)
(3) Tax in respect of earlier years	-	0.26	(0.77)	(0.51)	(0.73)
(4) Profit / (Loss) of Prior Period Depreciation					
	0.62	(41.17)	56.38	15.21	74.27
<b>XI. Profit (Loss) for the period from continuing operations (IX-X)</b>	<b>(52.13)</b>	<b>(117.25)</b>	<b>136.01</b>	<b>18.76</b>	<b>194.82</b>
XII. Profit/(loss) from discontinuing operations					
XIII. Tax expense of discontinuing operations					
XIV. Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)					
<b>XV. Profit (Loss) for the period (XI + XIV)</b>	<b>(52.13)</b>	<b>(117.25)</b>	<b>136.01</b>	<b>18.76</b>	<b>194.82</b>
<b>XVI. Earnings per equity share of Rs. 10 each</b>					
Basic	(1.66)	(3.73)	5.93	0.60	8.50
Diluted	(1.66)	(3.73)	5.93	0.60	8.50


Significant Accounting Policies  
The notes are integral parts of the financial statements

- The Above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing Regulations") have been approved by the Board of Directors at their respective meeting held on November 14, 2024. The Statutory Auditors of the company have carried out the audit of the aforesaid results for the half year and year ended 30th September, 2024. The Financial Results have been prepared in accordance with the Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with rules 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof.
- As per Ministry of Corporate Affairs Notification dated February 16,2015, Companies Whose Securities are listed on SME Exchange as referred in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.
- The above Standalone Financial Results have been reviewed by the Audit Committee and Approved by the Board of Directors at their respective meeting held on November 14, 2024 and have been audited by the Statutory Auditors of the Company.
- The Primary reporting of the company has been performed on the basis of business segment. The management of the company has evaluated the company's overall performance as one segment which is "Transforming Learning and Practice" and operates in a single business segment based on the nature of business, the risk and returns, the organisation structure and the internal control Financial systems. Accordingly, the figures appearing in these financial statements relate to the company's single business segment. The company has significant operations based in India, hence there are no reportable geographical segments in Standalone Financial Statements.
- The Figures for half year ended on 31st March 2024 are the balancing figures between the audited figures in respect of the financial year and the reviewed year to date figures for the half year ended on 30th September 2024.
- Previous period figures have been regrouped/reclassified and restated wherever considered necessary to make them comparable.
- The balance appearing under the trade payables, Loans & Advances, Other Current Liabilities are subject to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and/ or reconciliation.
- The company has issued and allotted 8,49,600 equity shares of Rs. 10 Each at premium of Rs.69 Per Equity Share through Initial Public Offer Aggregating to Rs. 671.18 Lakhs. The details of utilization of the net IPO proceeds is mentioned below:

Particulars	As per Prospectus	Funds Utilised
Purchase of IT infrastructure and operating system	303.08	258.08
Meeting incremental working capital requirements	200.00	200.00
General corporate purposes	103.10	103.10

For Docmode Health Technologies Limited

  
**Paulson Paul Thazhathodath**  
Whole Time Director  
Place : Mumbai  
November 14, 2024

  
**Hans Albert Lewis**  
Whole Time Director & CFO  
Place : Mumbai  
November 14, 2024

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
**Consolidated Statement of Cash Flows for the period ended September 30, 2024**

Indian Rupees in Lacs

(A) CASH FLOW FROM OPERATING ACTIVITIES	September 30,2024	March 31,2024
Net Profit before Tax and Extraordinary Items	(51.52)	33.97
<b>Adjusted for</b>		
Depreciation	14.14	2.44
Profit on Sale of Fixed Assets	-	-
Provision for Gratuity	(3.91)	17.43
Interest Expenses	109.26	165.72
<b>Operating Profit before Working Capital changes</b>	<b>67.98</b>	<b>219.56</b>
Adjustments for changes in working capital		
(Increase)/Decrease in Inventories	(108.97)	1.58
(Increase)/Decrease in Trade and Other Receivables	319.82	38.56
(Increase)/Decrease in Short Loans & Advances	(82.45)	29.47
(Increase)/Decrease in Long term Loans & Advances	(2.65)	(0.03)
(Increase)/Decrease in Other Current Assets	(15.40)	-
Increase/(Decrease) in Trade Payables	(60.42)	(21.81)
Increase/(Decrease) in Other Non Current liabilities	-	-
Increase/(Decrease) in Current liabilities	-	(0.41)
Increase/(Decrease) in Short Term Provisions	60.02	183.45
<b>Cash generated from operations</b>	<b>177.93</b>	<b>450.36</b>
Direct Taxes Paid	-	0.51
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>177.93</b>	<b>450.87</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Sale/ (Purchase) of Fixed Assets	(184.53)	(741.73)
Sale/ (Purchase) of Investments	(10.17)	(6.41)
Rent Deposit paid to landlord for office premises	0.22	(6.67)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(194.48)</b>	<b>(754.81)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds/(Repayment) from long term borrowings	(185.96)	(3.29)
Proceeds from Short Term Borrowings	213.20	73.37
Proceeds from issue of Shares	-	671.18
Interest paid	(109.26)	(165.72)
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>(82.02)</b>	<b>575.54</b>
NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(98.56)	271.60
OPENING BALANCE OF CASH AND CASH EQUIVALANTS	310.28	38.68
CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	211.72	310.28

**for DocMode Health Technologies Limited**



**Paulson Paul Thazhathadath**

Whole Time Director  
DIN 02301881



**Hans Albert Lewis**

Whole Time Director &  
CFO  
DIN 02301853  
PAN: ACOPL6883G



**Independent Auditor's Limited review Report on Unaudited Half Yearly Standalone financial Results of Docmode Health Technologies Limited under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as amended**

To,  
The Board of Directors,  
Docmode Health Technologies Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results ("The Statement") of **Docmode Health Technologies Limited** ("The Company") for the half year ended September 30, 2024 attached herewith, being submitted by the company to the stock exchange pursuant to the requirement of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) regulations, 2015. ("Listing Regulations").
2. This statement which is responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Accounting Standard "Interim Financial Reporting" prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the entity", issued by The Institute of Chartered Accountants of India. This standard required that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applicable to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result has not been prepared in accordance with applicable accounting standard and other recognized accounting practices and other accounting policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R. Sundaresan Aiyar & Co  
Chartered Accountants  
FRN: 110564W

R. Sundaresan Aiyar  
Partner

M.No - 043946

Date: 11/02/2025 Place: Mumbai

UDIN : 25043946BMIQRX8886



**Independent Auditor's Limited review Report on Unaudited Half Yearly Consolidated financial Results of Docmode Health Technologies Limited under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as amended**

To,  
The Board of Directors,  
Docmode Health Technologies Limited

1. We have reviewed the accompanying Statement of **Unaudited Consolidated Financial Results** ("The Statement") of **Docmode Health Technologies Limited** ("The Company") for the half year ended September 30, 2024 attached herewith, being submitted by the company to the stock exchange pursuant to the requirement of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) regulations, 2015. ("Listing Regulations").
2. This statement which is responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Accounting Standard "Interim Financial Reporting" prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the entity", issued by The Institute of Chartered Accountants of India. This standard required that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applicable to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of **unaudited financial result** has not been prepared in accordance with applicable accounting standard and other recognized accounting practices and other accounting policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R. Sundaresan Aiyar & Co  
Chartered Accountants  
FRN: - 110564W

CA R Sundaresan Aiyar  
Partner  
M.No - 043946  
Date: 11/02/2025  
Place: Mumbai

UDIN : 25043946BM!QRY8203



# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

Annexure-II

**Date:** 16.11.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of Outcome of the Board Meeting scheduled to be held on 14<sup>th</sup> November, 2024**

Dear Sir/ Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the outcome of the board meeting must be submitted within 30 minutes of its conclusion. Additionally, half-yearly unaudited standalone and consolidated financial results, along with a limited review report ("Financial Results"), should be submitted within 45 days, by November 14, 2024, for the half-year ending September 30, 2024.

In accordance with the above, we would like to inform you that R. Sundaresan Aiyar & Co, Chartered Accountants (Firm Registration No.: 110564W, M. No.: 043946), is the statutory auditor of our company. The peer review certification for the firm expired on September 30, 2024. To avoid delays, the firm applied for renewal on June 30, 2024, anticipating that the renewal would be completed within approximately one and a half months.

Given this timeline, the board meeting for the approval of the financial results for the period ended 30<sup>th</sup> September, 2024, was scheduled for 14 November, 2024. However, despite the extended waiting period and consistent follow-ups with the concerned authority, the peer review certification was not renewed by 14<sup>th</sup> November, 2024. As a result, although the board approved the financial results in the meeting held on 14<sup>th</sup> November, 2024, the statutory auditor could not sign them.

Due to this, the company was unable to publish the approved financial results to the NSE on 14<sup>th</sup> November, 2024, and expects to submit the signed financial results on or before 30<sup>th</sup> November, 2024, upon renewal of peer review registration of the statutory auditor of the company.

It was presumed that the outcome of the board meeting had been submitted to the NSE within 30 minutes of the meeting's conclusion. However, due to miscommunication and inadvertent human error, it was later realized that this intimation had not been made. We are now submitting the outcome of the board meeting, along with this clarification note, for your perusal.

We would like to emphasize that this oversight was unintentional and does not imply any misinformation regarding our company. We understand the critical importance of accurate and timely reporting, and we sincerely apologize for any confusion this may have caused.

Furthermore, as directed, we are resubmitting the proceedings of the board meeting along with this clarification regarding the delay in submission.

## **DocMode Health Technologies Limited**

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



**www.docmode.org**

Transforming Learning and Practice

---

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

---

**PAULSON PAUL THAZHATHEDATH**

**WHOLETIME DIRECTOR**

**DIN: 02301881**

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 16.11.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject:** Outcome of the Board Meeting dated 14<sup>th</sup> November, 2024

**Reference:** Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Schedule III of the Listing Regulations

Meeting Commencement Time	1.00 P.M
Meeting Conclusion Time	1.30 P.M

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform you that the Board of Directors of the Company, at its meeting held today i.e., Thursday, 14<sup>th</sup> November 2024 has considered and transacted the business of Financial Results as under:

We would like to inform you that the Financial Results for the period ending 30<sup>th</sup> September, 2024, have been approved by the Board of Directors of the company. However, due to the expiration of the statutory auditor’s peer review registration, the auditor has not yet signed the Financial Results. The statutory auditor has informed the company that the renewal process is underway and that signed Financial Results are expected to be provided on or before 30<sup>th</sup> November, 2024.

The Board has taken note of this situation and will make every effort to submit the signed Financial Results within the prescribed time period as outlined in this communication.

We sincerely apologize for any inconvenience caused to our shareholders.

Thank you for your understanding.

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 19.11.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of financial results for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of Board Meeting held on 14<sup>th</sup> November, 2024 submitted on 16<sup>th</sup> November, 2024, we are hereby submitting unaudited standalone and consolidated financial statements for your perusal.

We kindly request you to consider our financial results and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETEIME DIRECTOR**  
**DIN: 02301881**

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 29.11.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of Limited Review Report (Standalone & Consolidated) for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant the outcome of the Board meeting held on 14<sup>th</sup> November, 2024, and submitted on 16<sup>th</sup> November, 2024, along with the financial results submitted on 19<sup>th</sup> November, 2024 (including results in XBRL on 20<sup>th</sup> Novemebr, 2024), it was communicated in our previous submission that we would be publishing the signed limited review reports (Standalone & Consolidated) on or before 30<sup>th</sup> November, 2024, subject to the peer review renewal of the company's statutory auditor.

However, despite the continuous efforts of the Statutory Auditors, the peer review certification has not yet been renewed, preventing us from submitting the signed limited review reports (Standalone & Consolidated) by the previously stated deadline of 30<sup>th</sup> November, 2024. We now anticipate submitting the reports on or before 20<sup>th</sup> December, 2024, subject to the renewal of the statutory auditor's peer review registration.

We would like to emphasize that this oversight is unintentional and does not imply any misinformation regarding our company. We understand the critical importance of accurate and timely reporting, and we sincerely apologize for any confusion this may have caused.

We kindly request you to consider our concern over the technical issue and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

Digitally signed by  
PAULSON PAUL  
THAZHATHEDATH  
Date: 2024.11.29  
19:29:24 +05'30'

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 18.12.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of Limited Review Report (Standalone & Consolidated) for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of the Board meeting held on 14th November 2024, and the subsequent submissions made on 16th November 2024, along with the financial results submitted on 19th November 2024 (including XBRL results submitted on 20th November 2024) and the last intimation submitted on 29th November 2024, it was communicated in our earlier submission that the signed limited review reports (Standalone & Consolidated) would be published on or before 20th December 2024, subject to the peer review renewal of the company's statutory auditor.

However, despite the continuous efforts of the Statutory Auditors, the peer review certification has not yet been renewed. The auditor is making every effort and is expected to complete the peer review audit process within a few days, following which the CA Institute will approve the renewal of the peer review certification. Considering the time required for this process, we anticipate submitting the limited review reports on or before 15th January 2024.

We would like to emphasize that this oversight is unintentional and does not imply any misinformation regarding our company. We understand the critical importance of accurate and timely reporting, and we sincerely apologize for any confusion this may have caused.

We kindly request you to consider our concern over the technical issue and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

PAULSON PAUL  
THAZHATHEDATH

Digital signed by PAULSON PAUL THAZHATHEDATH  
DN: cn=PAULSON PAUL, o=DOCMODE HEALTH TECHNOLOGIES LIMITED, ou=DOCMODE HEALTH TECHNOLOGIES LIMITED, email=paul@docmode.org, c=IN  
Date: 2024.12.18 12:53:44 +05:30

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**



# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 15.01.2025

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of Limited Review Report (Standalone & Consolidated) for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of the Board meeting held on 14<sup>th</sup> November 2024, and the subsequent submissions made on 16<sup>th</sup> November 2024, along with the financial results submitted on 19<sup>th</sup> November 2024 (including XBRL results submitted on 20<sup>th</sup> November 2024) and the last intimation submitted on 29<sup>th</sup> November 2024, it was communicated in our earlier submission that the signed limited review reports (Standalone & Consolidated) would be published on or before 15<sup>th</sup> January 2025, subject to the peer review renewal of the company's statutory auditor.

Despite the ongoing efforts of the Statutory Auditors, the renewal of the peer review certification is still pending. The Auditor is currently awaiting approval from the CA Institute for the certification renewal. Given the time needed for approval, we expect to submit the limited review reports by 1<sup>st</sup> February, 2025, or earlier.

We would like to emphasize that this oversight is unintentional and does not imply any misinformation regarding our company. We understand the critical importance of accurate and timely reporting, and we sincerely apologize for any confusion this may have caused.

We kindly request you to consider our concern over the technical issue and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

PAULSON  
PAUL  
THAZHATHEDATH  
DATH

Digitally signed by  
PAULSON PAUL  
THAZHATHEDATH  
Date: 2025.01.15  
16:12:38 +05'30'

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 31.01.2025

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of Limited Review Report (Standalone & Consolidated) for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of the Board meeting held on 14<sup>th</sup> November 2024, and the subsequent submissions made on 16<sup>th</sup> November 2024, along with the financial results submitted on 19<sup>th</sup> November 2024 (including XBRL results submitted on 20<sup>th</sup> November 2024) and the last intimation submitted on 15<sup>th</sup> January 2025, it was communicated in our earlier submission that the signed limited review reports (Standalone & Consolidated) would be published on or before 01<sup>st</sup> February, 2025, subject to the peer review renewal of the company's statutory auditor.

Despite the ongoing efforts of the Statutory Auditors, the renewal of the peer review certification is still pending. The Auditor is currently awaiting approval from the CA Institute for the certification renewal. Given the time needed for approval, we expect to submit the limited review reports by 28<sup>th</sup> February, 2025, or earlier.

We would like to emphasize that this oversight is unintentional and does not imply any misinformation regarding our company. We understand the critical importance of accurate and timely reporting, and we sincerely apologize for any confusion this may have caused.

We kindly request you to consider our concern over the technical issue and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**

PAULSON PAUL THAZHATHEDATH  
TH  
Digitally signed by  
PAULSON PAUL  
THAZHATHEDATH  
Date: 2025.01.31  
13:26:50 +05'30'

**PAULSON PAUL THAZHATHEDATH**  
**WHOLETIME DIRECTOR**  
**DIN: 02301881**